Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

STAMFORD, Conn., March 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new ...

Perhaps no technology better embodies the spirit of the post-genomics age than the microarray. If genome sequencing projects listed the parts that make up an organism – be it a mouse, a fly, or a ...

A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children. This shift could enable earlier diagnoses for families and save ...

As newborn screening programs expand to include babies’ entire genomes, parents must be made aware of the privacy risks and states must create rules to rein in unbridled police access to this data.